Distributor inventory | Tablet
Glimepiride 1 mg + Metformin hydrochloride 1000 mg (modified release/extended release)
Type 2 diabetes mellitus in adults when diet and exercise alone or single-drug therapy does not provide adequate glycaemic control
Glimepiride (a sulfonylurea) increases insulin release from pancreatic beta cells and improves peripheral glucose utilization. Metformin decreases hepatic glucose production and improves insulin sensitivity, reducing intestinal glucose absorption. The combination lowers fasting and post‑meal blood glucose.
Take by mouth as prescribed, usually once daily with the first main meal (or as advised). Swallow tablet whole; do not crush or chew (MR/ER). Follow diet and exercise advice; monitor blood glucose regularly.
Common side effects of ZORYL M D 1/1000 TAB may include:
Risk of hypoglycaemia (higher with missed meals, alcohol, strenuous exercise, elderly); carry glucose source. Metformin may rarely cause lactic acidosis—avoid in severe kidney impairment, severe dehydration, sepsis, hypoxia, or severe liver disease; assess eGFR before and during therapy. Temporarily stop metformin before/after iodinated contrast procedures and major surgery as advised. Use caution in heart failure and in people with vitamin B12 deficiency (long‑term metformin can lower B12). Do not use in type 1 diabetes or diabetic ketoacidosis.
